[HTML][HTML] Unexpected new roles for heparanase in Type 1 diabetes and immune gene regulation

CR Parish, C Freeman, AF Ziolkowski, YQ He… - Matrix biology, 2013 - Elsevier
CR Parish, C Freeman, AF Ziolkowski, YQ He, EL Sutcliffe, A Zafar, S Rao, CJ Simeonovic
Matrix biology, 2013Elsevier
Heparanase (Hpse) is an endo-β-d-glucuronidase that degrades the glycosaminoglycan
heparan sulfate (HS) in basement membranes (BMs) to facilitate leukocyte migration into
tissues. Heparanase activity also releases HS-bound growth factors from the extracellular
matrix (ECM), a function that aids wound healing and angiogenesis. In disease states, the
degradation of HS in BMs by heparanase is well recognized as an invasive property of
metastatic cancer cells. Recent studies by our group, however, have identified unexpected …
Heparanase (Hpse) is an endo-β-d-glucuronidase that degrades the glycosaminoglycan heparan sulfate (HS) in basement membranes (BMs) to facilitate leukocyte migration into tissues. Heparanase activity also releases HS-bound growth factors from the extracellular matrix (ECM), a function that aids wound healing and angiogenesis. In disease states, the degradation of HS in BMs by heparanase is well recognized as an invasive property of metastatic cancer cells. Recent studies by our group, however, have identified unexpected new roles for heparanase and HS. First, we discovered that in Type 1 diabetes (T1D) (i) HS in the pancreatic islet BM acts as a barrier to invading cells and (ii) high levels of HS within the insulin-producing islet beta cells themselves are critical for beta cell survival, protecting the cells from free radical-mediated damage. Furthermore, catalytically active heparanase produced by autoreactive T cells and other insulitis mononuclear cells was shown to degrade intra-islet HS, increasing the susceptibility of islet beta cells to free radical damage and death. This totally novel molecular explanation for the onset of T1D diabetes opens up new therapeutic approaches for preventing disease progression. Indeed, administration of the heparanase inhibitor, PI-88, dramatically reduced T1D incidence in diabetes-prone NOD mice, preserved islet beta cell HS and reduced islet inflammation. Second, in parallel studies it has been shown that heparanase and HS can be transported to the nucleus of cells where they impact directly or indirectly on gene transcription. Based on ChIP-on-chip studies heparanase was found to interact with the promoters and transcribed regions of several hundred genes and micro-RNAs in activated Jurkat T cells and up-regulate transcription, with many of the target genes/micro-RNAs being involved in T cell differentiation. At the molecular level, nuclear heparanase appears to regulate histone 3 lysine 4 (H3K4) methylation by influencing the recruitment of demethylases to transcriptionally active genes. These studies have unveiled new functions for heparanase produced by T lymphocytes, with the enzyme mediating unexpected intracellular effects on T cell differentiation and insulin-producing beta cell survival in T cell-dependent autoimmune T1D.
Elsevier